Alberta delays deadline for forced medication switch by six months

Home/Policies & Legislation | Posted 24/04/2020 post-comment0 Post your comment

The Canadian province of Alberta has delayed its introduction of a switching policy to biosimilars for patients using biologicals for six months.

Switching V19A17

In May 2019, the Canadian province of British Columbia introduced a policy of switching rheumatology patients to biosimilars [1]. Soon after, the province of Alberta also announced that it was considering plans to stop coverage of originator biologicals and switch patients to biosimilars for certain indications. The new policy, when introduced, would apply to the approximately 30,000 patients in Alberta living with inflammatory bowel disease (IBD) [2].

However, concerns were raised in Alberta about the safety of such a policy to switch patients stable on their current treatment and in fact Canadian gastroenterologist associations do not recommend non-medical switching for such patients [3].

The deadline for patients in Alberta to switch to biosimilars was the 1 July 2020. However, the province has now said that the deadline for patients taking a biological to switch to a biosimilar has been changed from 1 July 2020 to 15 January 2021.

Under Alberta’s government sponsored drug plan, biologicals cost more than CA$238 million in 2018‒19 fiscal year; and are going up an average 16.2% per year. The originator biologicals Remicade (infliximab), Humira (adalimumab) and Enbrel (etanercept) are three of the top four drivers of drug spending in Alberta.

The province believes that switching to biosimilars will save between CA$227 million and CA$380 million over the next four years once fully implemented. These savings, according to the province, ‘can be invested into other healthcare services for Albertans’.

The switch will affect not only patients using Enbrel, Humira and Remicade, but also patients using Lantus (insulin glargine) for diabetes and Neulasta (pegfilgrastim) for neutropenia [an abnormally low concentration of neutrophils (a type of white blood cell) in the blood]. In addition, the province also intends to switch patients using Copaxone (glatiramer), which is a non-biological complex drug, for multiple sclerosis.

Related articles
British Columbia releases latest data on biosimilar switches

Opposition party in Alberta, Canada fights biosimilar switching policy

Ontario becomes third Canadian province to switch patients to biosimilars

1. GaBI Online - Generics and Biosimilars Initiative. Law and ethics of switching to biosimilars in Canada []. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Apr 24]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. Concerns raised as Canada’s Alberta plans to switch patients to biosimilars []. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Apr 24]. Available from:
3. GaBI Online - Generics and Biosimilars Initiative. Canadian gastroenterologists issue biosimilar position statement []. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Apr 24]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. 

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

Source: Government of Alberta

comment icon Comments (0)
Post your comment
Related content
Panama embraces international pharmacovigilance standards
Pharmacovigilance V13F21
Home/Policies & Legislation Posted 09/07/2024
FDA proposal to remove biosimilar interchangeability status in FY25
01 AA007239
Home/Policies & Legislation Posted 12/06/2024
MHRA unveils strategy for regulating AI technologies
23 AA011020
Home/Policies & Legislation Posted 22/05/2024
Regulatory Certainty Strategy for biosimilars launched in Mexico
Home/Policies & Legislation Posted 09/04/2024
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010